Abdul Abdellatif, MD
Nephrology · Webster, TXNPI 1164560595
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,622,872 of the $2,064,398 with a category attached, or 78.6%. 46 manufacturers reported payments, led by Amgen at 38.4% of the total. Reporting peaked in 2022 at $444,326 and has fallen 56.0% since, to $195,384 in 2025. Among nephrology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,602 payments — averaging $793.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$793K
- Mallinckrodt Hospital Products Inc.$521K
- Aurinia Pharma U.S., Inc.$183K
- Travere Therapeutics, Inc.$129K
- Mallinckrodt Enterprises LLC$126K
- Bayer$122K
- plus $191K from 40 others
Across 53 payments — averaging $16,712 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$369K
- Eli Lilly$289K
- Vertex$121K
- Travere Therapeutics, Inc.$39K
- Aurinia Pharma U.S., Inc.$21K
- AstraZeneca$18K
- plus $28K from 3 others
What the payments were for
- Consulting fees$106,9235%
- Speaking & faculty fees$1,622,87279%
- Travel & lodging$290,08514%
- Food & beverage$43,5892%
- Education$8880%
- Gifts$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,064,398 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 11 | $502,276 |
| XphozahTenapanor Hcl | 69 | $207,176 |
| LupkynisVoclosporin | 12 | $119,900 |
| FarxigaDapagliflozin Propanediol | 116 | $112,376 |
| OzempicSemaglutide | 51 | $80,820 |
| Cinacalcet Hcl | 65 | $69,104 |
| AuryxiaFerric Citrate | 29 | $55,432 |
| RayaldeeCalcifediol | 33 | $46,743 |
| MounjaroTirzepatide | 36 | $40,643 |
| JardianceEmpagliflozin | 27 | $38,549 |
| ProcritEpoetin Alfa | 29 | $35,446 |
| RetacritEpoetin Alfa-Epbx | 44 | $32,530 |
| EliquisApixaban | 41 | $31,269 |
| Sevelamer Carbonate | 100 | $25,176 |
| LinzessLinaclotide | 23 | $20,981 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $793,345 | $502,27611 claims |
| Aurinia Pharma U.S., Inc.Lupkynis | $182,921 | $119,90012 claims |
| AstraZenecaFarxiga | $7,846 | $112,376116 claims |
| Novo NordiskOzempic | $293 | $80,82051 claims |
| PfizerRetacrit, Eliquis | $15 | $63,79985 claims |
| Akebia Therapeutics IncAuryxia | $31,403 | $55,43229 claims |
| Boehringer IngelheimJardiance, Tradjenta | $18 | $54,30145 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $231 | $46,74333 claims |
| Lilly USA, LLCMounjaro | $101 | $40,64336 claims |
| Johnson & JohnsonProcrit | $22,545 | $35,44629 claims |
| AbbVieLinzess | $44 | $20,98123 claims |
| MerckJanumet, Januvia | $30 | $20,88934 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Webster
- Tejinder AhujaWebster$59K
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
- Anand ReddyOdessa$469K
- Christopher KwohHouston$467K
- Wolfgang WinkelmayerHouston$462K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.